Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome

14 Apr 2014

Abstract excerpt

Intraclonal heterogeneity was recently described in multiple myeloma (MM), but its full impact on disease progression and relapse has not been entirely explored. The immunoglobulin type produced by myeloma cells provides an excellent marker to follow changes in clonal substructure over time. We have prospectively evaluated serial paraprotein and serum free light chain (FLC) measurements and found that 258 of 520...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glycosylation and Glycoproteins Research
Share to Monoclonal and Polyclonal Antibodies Research
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24733348
DOI: 10.1182/blood-2013-12-542662

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcomePMID 24733348Read ↗

Non-secretory multiple myeloma: from biology to clinical managementSemantic proximity Read ↗

Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myelomaSemantic proximity Read ↗

Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse.Semantic proximity Read ↗

Deep Sequencing Reveals Oligoclonality At The Immunoglobulin Locus In Multiple Myeloma PatientsSemantic proximity Read ↗

Measurable Residual Disease (MRD) dynamics in Multiple Myeloma and the influence of Clonal Diversity Analyzed by Artificial IntelligenceSemantic proximity Read ↗

Relapse prediction in multiple myeloma patients treated with isatuximab, carfilzomib, and dexamethasoneSemantic proximity Read ↗

Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myelomaSemantic proximity Read ↗

Mechanisms of the escape phase of myeloma.Semantic proximity Read ↗

Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.